上皮瘤治療市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、藥物類別、分銷管道、地區和競爭格局分類，2021-2031年）

全球上皮瘤治療市場預計將從 2025 年的 52.2 億美元成長到 2031 年的 87.5 億美元，複合年成長率為 8.99%。

該市場專注於治療性介入上皮來源腫瘤，特別是基底細胞癌和鱗狀細胞癌。其主要成長促進因素包括：由於紫外線累積照射導致全球皮膚惡性腫瘤發生率上升，以及人口老化加劇了人們對腫瘤疾病的易感性。此外，意識提升以及非侵入性治療方法的進步也顯著推動了對有效治療方案的需求。

儘管存在這些積極趨勢，但市場仍面臨許多障礙。根據美國癌症協會的數據，預計到2024年，美國將新增約100,640例黑色素瘤病例，凸顯了普及醫療保健的迫切需求。然而，先進免疫療法和標靶藥物的高成本構成了一項重大挑戰。這種經濟負擔往往限制了患者獲得新療法的機會，使醫保報銷機制複雜化，並可能阻礙市場進一步擴張。

市場促進因素

全球基底細胞癌和鱗狀細胞癌發生率的不斷上升是推動全球上皮瘤治療市場發展的主要因素。這一成長主要歸因於紫外線照射的累積以及人口老化加劇，老年人患皮膚惡性腫瘤的風險更高。隨著患者數量的增加，醫療保健系統也面臨手術切除和局部治療需求的相應成長，以應對日益沉重的負擔。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告，光是在美國，每年就有約540萬例基底細胞癌和鱗狀細胞癌確診病例。此外，澳洲輻射防護與核能在2024年預測，到2050年，基底細胞癌的發生率將增加148%，這將確保對治療性介入的長期持續需求。

標靶治療和免疫調節劑的技術突破正在同時革新進行性和轉移性上皮腫瘤的治療模式。程序性死亡蛋白-1 (PD-1) 抑制劑的商業化為不適合傳統手術或放射治療的患者提供了有效的替代方案。這些創新正在迅速普及，大型製藥公司的收入顯著成長便印證了這一點。例如，2024年2月，再生元製藥公司報告稱，其用於治療皮膚鱗狀細胞癌的主要免疫療法Libtayo的全球淨銷售額在2023年飆升50%，達到8.69億美元。這一強勁的財務表現凸顯了先進治療方法的積極應用，從而推動了對腫瘤學研究的進一步投資，並擴大了患者獲得拯救生命的生物療法的機會。

市場挑戰

先進免疫療法和標靶治療的高昂成本嚴重阻礙了上皮腫瘤治療領域的發展。這些高成本造成了複雜的健保報銷環境，保險公司經常限制對新型高價值藥物的承保。因此，患者往往需要承擔高額的自付費用，限制了這些治療方法的普及，迫使醫療服務提供者依賴價格更低廉的傳統治療方法。這種價格敏感度直接降低了製藥公司的收入潛力，並延緩了創新治療方法的商業化。

考慮到非黑色素瘤皮膚癌的臨床療效，這些經濟障礙的影響更為顯著。根據美國癌症協會預測，到2024年，基底細胞癌和鱗狀細胞癌預計將在美國造成約2,000人死亡。雖然這一死亡人數凸顯了有效治療性介入的緊迫性，但臨床需求與治療費用之間的脫節阻礙了市場擴張的潛力。新興治療方法的定價模式往往超過醫療保險機構的報銷門檻，導致市場難以將不斷成長的疾病盛行率轉化為持續的商業性成長。

市場趨勢

全球上皮瘤治療市場目前正經歷著向非侵入性和微創治療方法的重大轉變，這主要受患者對無疤痕治療方法切除方案的需求所驅動。這一趨勢的特徵是影像導引淺層放射治療（IG-SRT）的日益普及。 IG-SRT是一種能夠精準地將治療劑量傳送到基底細胞癌部位，且不會影響患者日常生活的技術。這種治療方法越來越受歡迎，尤其是在追求更佳美容效果的患者中，促使皮膚科診所拓展其非手術治療計畫。根據Sensus Healthcare公司（2025年11月）發布的2025年第三季財務報告，該公司「公平交易」合約模式下的治療數量在第三季度較第二季度成長了20%，證實了這種非侵入性治療方法在臨床上的快速應用。

同時，個人化醫療和基因組分析的應用正在從根本上改變高風險皮膚惡性腫瘤的臨床決策。臨床醫師正積極利用超越傳統分期系統的先進基因表現分析，以準確預測鱗狀細胞癌的轉移風險，並制定個人化的治療方案。這種精準的風險分層使醫療服務提供者能夠識別真正受益於輔助性治療的患者，同時避免低風險患者接受不必要的手術。這種向生物學指導治療的轉變得益於診斷利用率的顯著提高。根據Castle Biosciences公司於2025年11月發布的“2025年第三季財務業績”，該公司在截至2025年9月30日的九個月內發布了13,323份DecisionDx-SCC檢測報告，這表明該公司越來越依賴基因組數據來最佳化患者照護路徑。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球上皮瘤治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（基底細胞上皮瘤、鱗狀細胞癌、其他上皮腫瘤）
  • 依藥物類別（刺蝟訊號路徑抑制劑、免疫查核點抑制劑、化療藥物、其他）
  • 通路（醫院藥房、零售藥房、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美上皮腫瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲上皮腫瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區上皮腫瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲上皮腫瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲上皮腫瘤治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球上皮瘤治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Roche
• Merck
• Novartis
• Pfizer
• Bristol-Myers Squibb
• Sanofi
• Eli Lilly
• AstraZeneca
• Takeda
• Regeneron

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Epithelioma Treatment Market is projected to expand from a valuation of USD 5.22 Billion in 2025 to USD 8.75 Billion by 2031, progressing at a CAGR of 8.99%. This market centers on therapeutic interventions for tumors originating from the epithelium, specifically targeting Basal Cell Carcinoma and Squamous Cell Carcinoma. Key catalysts for growth include the rising global incidence of skin malignancies due to cumulative ultraviolet radiation exposure and an aging population increasingly susceptible to oncological conditions. Additionally, heightened public awareness regarding early skin examinations and advancements in non-invasive therapeutic modalities are significantly boosting the demand for effective treatment solutions.

Despite this positive trajectory, the market faces considerable impediments. Data from the American Cancer Society indicates that in 2024, approximately 100,640 new cases of melanoma were projected to be diagnosed in the United States, highlighting the urgent need for accessible care; however, the elevated costs associated with advanced immunotherapies and targeted pharmaceutical agents present a formidable challenge. This financial burden often restricts patient access to novel treatments and adds complexity to reimbursement landscapes, potentially hindering broader market expansion.

Market Driver

The escalating global prevalence of Basal Cell Carcinoma and Squamous Cell Carcinoma serves as the primary force driving the Global Epithelioma Treatment Market. This surge is largely attributed to cumulative ultraviolet radiation exposure and demographic shifts toward an older population susceptible to cutaneous malignancies. As patient numbers rise, healthcare systems are witnessing a parallel increase in the demand for surgical excisions and topical treatments to manage this growing burden. According to the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024, an estimated 5.4 million basal and squamous cell skin cancers are diagnosed annually in the United States alone. Furthermore, the Australian Radiation Protection and Nuclear Safety Agency projected in 2024 that the incidence of basal cell carcinoma would increase by 148% by 2050, ensuring sustained long-term demand for therapeutic interventions.

Technological breakthroughs in targeted therapies and immunomodulators are simultaneously revolutionizing the treatment landscape for advanced and metastatic epitheliomas. The commercialization of programmed cell death protein-1 (PD-1) inhibitors has provided effective alternatives for patients ineligible for conventional surgery or radiation. These innovations are rapidly gaining traction, evidenced by substantial revenue growth for key pharmaceutical players; for instance, Regeneron Pharmaceuticals, Inc. reported in February 2024 that global net sales for Libtayo, a primary immunotherapy for cutaneous squamous cell carcinoma, surged by 50% to reach $869 million in 2023. This robust financial performance highlights the aggressive adoption of sophisticated therapeutics, encouraging further investment in oncology research and widening access to life-saving biologic treatments.

Market Challenge

The substantial expense associated with advanced immunotherapies and targeted pharmaceutical agents acts as a significant barrier to the growth of the epithelioma treatment sector. These elevated costs create a difficult reimbursement environment where insurance providers frequently restrict coverage for newer, high-value drugs. Consequently, patients often face prohibitive out-of-pocket expenditures, which limits the adoption rate of these therapies and forces healthcare providers to rely on older, less expensive alternatives. This price sensitivity directly reduces the potential revenue volume for pharmaceutical developers and slows the commercialization of innovative solutions.

The impact of these financial barriers is magnified when considering the clinical outcomes associated with non-melanoma skin cancers. According to the American Cancer Society, in 2024, approximately 2,000 people were projected to die from basal and squamous cell skin cancers in the United States. While this mortality figure highlights the critical need for effective therapeutic intervention, the disparity between the clinical demand and the affordability of care hampers market scalability. As the pricing models for emerging therapies often exceed the reimbursement thresholds set by healthcare payers, the market struggles to convert the rising disease prevalence into sustained commercial expansion.

Market Trends

The Global Epithelioma Treatment Market is currently experiencing a decisive shift toward non-invasive and minimally invasive modalities, driven by patient demand for scar-free alternatives to traditional surgical excisions. This trend is characterized by the increasing adoption of Image-Guided Superficial Radiation Therapy (IG-SRT), a technology that delivers precise therapeutic doses to Basal Cell and Squamous Cell Carcinomas without disrupting daily activities. This modality is particularly gaining traction among patients seeking superior cosmetic outcomes, prompting dermatology practices to expand their non-surgical service offerings. According to Sensus Healthcare, Inc., November 2025, in the 'Third Quarter 2025 Financial Results', the treatment volume under the company's Fair Deal Agreement model increased by 20% in the third quarter compared to the second quarter of 2025, underscoring the rapid clinical uptake of this non-invasive intervention.

Simultaneously, the implementation of personalized medicine and genomic profiling is fundamentally reshaping clinical decision-making for high-risk cutaneous malignancies. Clinicians are increasingly utilizing advanced gene expression profile tests to accurately predict the risk of metastasis in Squamous Cell Carcinoma, moving beyond traditional staging systems to tailor treatment intensity. This precise risk stratification enables healthcare providers to identify patients who truly benefit from adjuvant therapies while sparing low-risk individuals from unnecessary procedures. This shift towards biologically guided management is evidenced by significant diagnostic utilization; according to Castle Biosciences, Inc., November 2025, in the 'Third Quarter 2025 Results', the company delivered 13,323 DecisionDx-SCC test reports during the nine months ended September 30, 2025, highlighting the growing reliance on genomic data to optimize patient care pathways.

Key Market Players

• Roche
• Merck
• Novartis
• Pfizer
• Bristol-Myers Squibb
• Sanofi
• Eli Lilly
• AstraZeneca
• Takeda
• Regeneron

Report Scope

In this report, the Global Epithelioma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epithelioma Treatment Market, By Type

• Basal Cell Epithelioma
• Squamous Cell Epithelioma
• Other Epitheliomas

Epithelioma Treatment Market, By Drug Class

• Hedgehog Pathway Inhibitors
• Immune Checkpoint Inhibitors
• Chemotherapeutic Agents
• Others

Epithelioma Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other

Epithelioma Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Epithelioma Treatment Market.

Available Customizations:

Global Epithelioma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epithelioma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Basal Cell Epithelioma, Squamous Cell Epithelioma, Other Epitheliomas)
  • 5.2.2. By Drug Class (Hedgehog Pathway Inhibitors, Immune Checkpoint Inhibitors, Chemotherapeutic Agents, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Epithelioma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Epithelioma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Epithelioma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Epithelioma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel

7. Europe Epithelioma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Epithelioma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Epithelioma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Epithelioma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Epithelioma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Epithelioma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Epithelioma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Epithelioma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Epithelioma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Epithelioma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Epithelioma Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Epithelioma Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Epithelioma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Epithelioma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Epithelioma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Epithelioma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel

10. South America Epithelioma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Epithelioma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Epithelioma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Epithelioma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Epithelioma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Roche
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck
• 15.3. Novartis
• 15.4. Pfizer
• 15.5. Bristol-Myers Squibb
• 15.6. Sanofi
• 15.7. Eli Lilly
• 15.8. AstraZeneca
• 15.9. Takeda
• 15.10. Regeneron

16. Strategic Recommendations

17. About Us & Disclaimer